The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1.

A descriptor based computational model was developed for cytochrome P450 2E1 (CYP2E1) based on inhibition constants determined for inhibition of chlorzoxazone, or 4-nitrophenol, metabolism. An empirical descriptor for type II binding was developed and tested for a series of CYP2E1 inhibitors. Inhibition constants where measured for 51 different compounds. A fast 2-dimensional predictive model was developed based on 40 compounds, and tested on 8 compounds of diverse structure. The trained model (n=40) had an r(2) value of 0.76 and an RMSE of 0.48. The correlation between the predicted and actual pK(i) values of the test set of compounds not included in the model gives an r(2) value of 0.78. The features that described binding include heme coordination (type II binding), molecular volume, octanol/water partition coefficient, solvent accessible surface area, and the sum of the atomic polarizabilities. The heme coordination parameter assigns an integer between 0 and 6 depending on structure, and is a new descriptor, based on simple quantum chemical calculations with correction for steric effects. The type II binding parameter was found to be important in obtaining a good correlation between predicted and experimental inhibition constants increasing the r(2) value from 0.38 to 0.77.

[1]  D. Rock,et al.  An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[2]  Xiaodong Zhang,et al.  Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. , 2004, Biochemical pharmacology.

[3]  Jeffrey P. Jones,et al.  Formation of the active species of cytochrome p450 by using iodosylbenzene: a case for spin-selective reactivity. , 2007, Chemistry.

[4]  J. Jones,et al.  Metabolism of 1,2-dichloro-1-fluoroethane and 1-fluoro-1,2,2-trichloroethane: electronic factors govern the regioselectivity of cytochrome P450-dependent oxidation. , 1996, Chemical research in toxicology.

[5]  M. Dowsett,et al.  Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  Jeffrey P. Jones,et al.  Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues. , 2008, Journal of medicinal chemistry.

[7]  M. Gelb,et al.  A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  O. Martins-Filho,et al.  A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. , 2000, The Journal of antimicrobial chemotherapy.

[9]  R. Tyndale,et al.  Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking , 2000, Clinical pharmacology and therapeutics.

[10]  Jeffrey P. Jones,et al.  Line-walking method for predicting the inhibition of P450 drug metabolism. , 2006, Journal of medicinal chemistry.

[11]  P. Wincker,et al.  Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870 , 1996, Science.

[12]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[13]  Sason Shaik,et al.  A density functional study of the factors that influence the regioselectivity of toluene hydroxylation by cytochrome P450 enzymes , 2007 .

[14]  Nikhil S. Ketkar,et al.  High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. , 2008, Journal of medicinal chemistry.

[15]  J. Vacca,et al.  P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Timothy S Tracy,et al.  Visible Spectra of Type II Cytochrome P450-Drug Complexes: Evidence that “Incomplete” Heme Coordination Is Common , 2007, Drug Metabolism and Disposition.

[17]  Honggang Hu,et al.  Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase. , 2009, European journal of medicinal chemistry.

[18]  P. Beaune,et al.  Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. , 1991, Chemical research in toxicology.

[19]  Jeffrey P. Jones,et al.  Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101). , 2003, Biochemistry.

[20]  Jeffrey P. Jones,et al.  Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Rosales-Hernández,et al.  Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays. , 2010, European journal of medicinal chemistry.

[22]  Nina Isoherranen,et al.  Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. , 2006, Biochemistry.

[23]  C. Tang,et al.  P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes. , 2001, Biochemical pharmacology.

[24]  D. Koop.  Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a. , 1986, Molecular pharmacology.

[25]  Jeffrey P. Jones,et al.  KINETIC ISOTOPE EFFECTS IMPLICATE A SINGLE OXIDANT FOR CYTOCHROME P450-MEDIATED O-DEALKYLATION, N-OXYGENATION, AND AROMATIC HYDROXYLATION OF 6-METHOXYQUINOLINE , 2006, Drug Metabolism and Disposition.

[26]  J. Schlatter,et al.  Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. , 2002, Environmental health perspectives.

[27]  C. Lieber,et al.  Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. , 1989, Archives of biochemistry and biophysics.

[28]  R. Tyndale,et al.  Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  J. Schenkman.  Studies on the nature of the type I and type II spectral changes in liver microsomes. , 1970, Biochemistry.

[30]  R. Vestal,et al.  Dose‐dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics , 1989, Clinical pharmacology and therapeutics.

[31]  Jeffrey P. Jones,et al.  The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4. , 2010, Archives of biochemistry and biophysics.

[32]  G. Gibbons.  The role of cytochrome P450 in the regulation of cholesterol biosynthesis , 2002, Lipids.

[33]  M. J. Coon,et al.  Purification of liver microsomal cytochrome P-450 isozymes 3a and 6 from imidazole-treated rabbits. Evidence for the identity of isozyme 3a with the form obtained by ethanol treatment. , 1984, Molecular pharmacology.

[34]  T. Tracy,et al.  Rapid and sensitive high-performance liquid chromatographic assay for 6-hydroxychlorzoxazone and chlorzoxazone in liver microsomes. , 1997, Journal of chromatography. B, Biomedical sciences and applications.